<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04784312</url>
  </required_header>
  <id_info>
    <org_study_id>9MW1411-2020-CP101</org_study_id>
    <nct_id>NCT04784312</nct_id>
  </id_info>
  <brief_title>A Clinical Study in Health Subjects to Evaluate 9MW1411 Injection</brief_title>
  <official_title>A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Immunogenicity of a Single Dose of MW14 Injection in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mabwell (Shanghai) Bioscience Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mabwell (Shanghai) Bioscience Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, first time in human study enrolling approximately 42 healthy adult&#xD;
      subjects (18-45 yrs) from one study site. The purpose of this study is to evaluate the&#xD;
      safety, tolerability and PK of MW14 in healthy adult volunteers administered as a single IV&#xD;
      dose compared with placebo, across 5 cohorts. The 5 dose cohorts will enroll sequentially.&#xD;
      Subjects will be followed for safety from the time of Informed Consent through 85 days post&#xD;
      dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 16, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>12 weeks</time_frame>
    <description>safety evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Event</measure>
    <time_frame>12 weeks</time_frame>
    <description>safety evaluation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Staphylococcus Aureus Infection</condition>
  <arm_group>
    <arm_group_label>9MW1411 injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>9MW1411 injection placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>9MW1411 injection</intervention_name>
    <description>9MW1411 injection</description>
    <arm_group_label>9MW1411 injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>9MW1411 injection placebo</intervention_name>
    <description>9MW1411 injection placebo</description>
    <arm_group_label>9MW1411 injection placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects aged 18 to 45 years (including 18 and 45 years).&#xD;
&#xD;
          2. Weight≥50.0 kg for males, or weight≥45.0 kg for females, and body mass index (BMI) in&#xD;
             the range of 19.0 ~ 26.0 kg/m2 (including cut-off value).&#xD;
&#xD;
          3. The medical history, physical examination, clinical laboratory tests and other tests&#xD;
             related study show no abnormalities, or abnormalities without clinical significance.&#xD;
&#xD;
          4. Subjects do not have a pregnancy plan, have no sperm and egg donation plans during the&#xD;
             screening period and the next 6 months, and take effective contraceptive measures&#xD;
             voluntarily.&#xD;
&#xD;
          5. Are willing to follow study procedures, signed informed consent voluntarily, and&#xD;
             ensure that he/she will complete the study according to the program requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Prior or current medical conditions:&#xD;
&#xD;
          1. Health status: clinically significant histories of heart, liver, kidney, digestive&#xD;
             tract, nervous system, respiratory system, blood and lymphatic system, immune system,&#xD;
             mental, metabolic, and bone abnormalities.&#xD;
&#xD;
          2. Subjects who have a history of allergies to biological agents or any drug components;&#xD;
             those who have a history of allergies and judged by the investigator to be ineligible&#xD;
             for enrollment.&#xD;
&#xD;
          3. Those who undergone acute infection within 2 weeks prior to screening.&#xD;
&#xD;
          4. Those with abnormalities in pulmonary imaging examination prior to screening and&#xD;
             judged to be clinically significant by the investigator.&#xD;
&#xD;
          5. Those who have undergone surgery within 3 months prior to screening, or who plan to&#xD;
             undergo surgery during the study.&#xD;
&#xD;
          6. Those who cannot tolerate venipuncture or have a history of needle-sickness and&#xD;
             blood-sickness.&#xD;
&#xD;
          7. Those who have a history of drug abuse within 6 months prior to screening.&#xD;
&#xD;
          8. Use of illicit drugs within 3 months prior to screening.&#xD;
&#xD;
          9. Those who donated blood within 3 months prior to screening (including component&#xD;
             blood), or massive blood loss (≥ 200 mL), or blood transfusions or use of blood&#xD;
             products.&#xD;
&#xD;
         10. Subject (female) who is pregnant or lactating at screening or during the trial.&#xD;
&#xD;
         11. Subjects have a fertility plan or sperm or egg donation plan at screening and within&#xD;
             the next 6 months.&#xD;
&#xD;
         12. Use of any prescription, over-the-counter, or Chinese herbal medicines within 2 weeks&#xD;
             prior to screening.&#xD;
&#xD;
         13. Those who have been vaccinated within 4 weeks prior to screening or who are scheduled&#xD;
             to be vaccinated during the study.&#xD;
&#xD;
         14. Those who have smoked more than 5 cigarettes per day within 3 months prior to&#xD;
             screening.&#xD;
&#xD;
         15. Those who have consumed more than 14 units of alcohol per week (1 unit of alcohol ≈&#xD;
             360 mL of beer or 45 mL of spirits containing 40% alcohol or 150 mL of wine) within 3&#xD;
             months prior to screening, or who cannot abstain from alcohol during the trial.&#xD;
&#xD;
         16. Those who have special dietary requirements and cannot accept a standard diet.&#xD;
&#xD;
         17. Those who have participated in drug or medical devices clinical trials within 3 months&#xD;
             prior to screening.&#xD;
&#xD;
         18. Those who have previously used immunosuppressants or monoclonal antibodies for any&#xD;
             reason.&#xD;
&#xD;
         19. Those with abnormal vital signs with clinical significance: diastolic blood&#xD;
             pressure≤50 mmHg or ≥90 mmHg, pulse≤50 beats/min or ≥100 beats/min, body temperature&#xD;
             (ear temperature) &lt;35.5°C or &gt;37.5°C, respiration&gt;20 breaths/min. The specific&#xD;
             situation will be comprehensively determined by the investigator.&#xD;
&#xD;
         20. Those with abnormalities in laboratory tests and auxiliary examinations that are&#xD;
             judged by the investigator to be clinically significant.&#xD;
&#xD;
         21. Those who have one or more clinically significant tests of hepatitis B virological&#xD;
             markers, hepatitis C virus antibodies, anti-human immunodeficiency virus antibodies,&#xD;
             or anti-Treponema pallidum-specific antibodies.&#xD;
&#xD;
         22. Female subjects with a positive blood pregnancy test at screening.&#xD;
&#xD;
         23. Alcohol breath test results greater than 0.0 mg/100 ml or positive drug screening&#xD;
             (morphine, icenarcotics [methamphetamine], ketamine, ecstasy&#xD;
             [methylenedioxyamphetamine], cannabis [tetrahydrocannabinolate], erythroxylin).&#xD;
&#xD;
         24. Subjects who is inappropriate to participate in the trial due to any reasons as&#xD;
             determined by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Huashan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

